<p><strong>Pediatric patients</strong>: Silodosin is not indicated for use in pediatric patients.<br />
<br />
<strong>Geriatric use</strong>: In double-blind, placebo-controlled, 12-week clinical studies of Silodosin, 259 (55.6%) were under 65 years of age, 207 (44.4%) patients were 65 years of age and over, while 60 (12.9%) patients were 75 years of age and over. Orthostatic hypotension was reported in 2.3% of Silodosin patients &lt; 65 years of age (1.2% for placebo), 2.9% of Silodosin patients &gt; 65 years of age (1.9% for placebo), and 5.0% of patients &gt; 75 years of age (0% for placebo). There were otherwise no significant differences in safety or effectiveness between older and younger patients.<br />
<br />
<strong>Renal impairment</strong>: Silodosin is contra-indicated in patients with severe renal impairment (CCr &lt;30 mL/min). In patients with moderate renal impairment (CCr 30-50 mL/min), the dose should be reduced to Silodosin 4 mg once daily taken with a meal. No dosage adjustment is needed in patients with mild renal impairment (CCr 50-80 mL/min).<br />
<br />
<strong>Hepatic impairment</strong>: Silodosin has not been studied in patients with severe hepatic impairment (Child-Pugh score &gt;10) and is therefore contra-indicated in these patients. No dosage adjustment is needed in patients with mild or moderate hepatic impairment.</p>